Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ST-01156 in Advanced Solid Malignancies
NCT07197554Phase 1Recruiting
- Sponsor
- SEED Therapeutics
- Start
- Dec 2025
- Primary completion
- Dec 2029
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ST-01156 in solid tumor, Ewing sarcoma, hepatocellular carcinoma (HCC) and 1 more, sponsored by SEED Therapeutics. Primary endpoints: Safety and Tolerability (Dose-Limiting Toxicities) and Overall Safety and Tolerability. Started Dec 2025; status: recruiting.
02
Drugs
ST-01156
03
Conditions
solid tumorEwing sarcomahepatocellular carcinoma (HCC)biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT07197554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07197554.